Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/NMPA/Valsartan and Hydrochlorothiazide Tablets

Approved

化学药品

Valsartan and Hydrochlorothiazide Tablets

辰欣药业股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Jun 30, 2022
Approval ID: 8HfEYZ15Tfo
Company: 辰欣药业股份有限公司
Type: 化学药品

Approval Details

Approval Id: 8HfEYZ15Tfo
Approval Number: 国药准字H20223460
Generic Name: 缬沙坦氢氯噻嗪片
Generic Name En: Valsartan and Hydrochlorothiazide Tablets
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 每片含缬沙坦80mg，氢氯噻嗪12.5mg
Reg Date: 2022-06-30
Company Name: 辰欣药业股份有限公司
Company Address: 济宁高新区同济科技工业园
Production Company Name: 辰欣药业股份有限公司;华益泰康药业股份有限公司
Production Company Address: 济宁高新区海川路；海口市南海大道273号海口高新区D栋轻钢结构标准工业厂房西侧
Company Detail Path: /organization/cisen-pharmaceutical-co-ltd

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jun 30, 2022

Approval ID

8HfEYZ15Tfo

Type

化学药品

Back to NMPA Approvals

缬沙坦氢氯噻嗪片 - NMPA Drug Approval Details